Last reviewed · How we verify
American Scitech International — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| R-mabHDI and ABVD | R-mabHDI and ABVD | phase 3 | Monoclonal antibody + chemotherapy combination | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AryoGen Pharmed Co. · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 shared drug class
- Cinnagen · 1 shared drug class
- Fondazione Italiana Linfomi - ETS · 1 shared drug class
- Fujian Medical University · 1 shared drug class
- Nordic Lymphoma Group · 1 shared drug class
- Prof. Dr. M. Dreyling (co-chairman) · 1 shared drug class
- Shandong Provincial Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for American Scitech International:
- American Scitech International pipeline updates — RSS
- American Scitech International pipeline updates — Atom
- American Scitech International pipeline updates — JSON
Cite this brief
Drug Landscape (2026). American Scitech International — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-scitech-international. Accessed 2026-05-16.